Cato Daily Podcast
Would Wider Access to GLP-1s Throttle Addiction?
Jan 31, 2025
Nicholas Reville, Director of CASPR and an expert in addiction medicine, discusses the promising use of GLP-1 drugs like Ozempic in combating addiction. He argues for wider access to these medications, highlighting their potential to mitigate cravings linked to substance use disorders. The conversation touches on the off-label use of these drugs, the importance of ongoing research, and the role of compounding pharmacies in improving accessibility. Reville also calls for policy changes to encourage more pharmaceutical investment in addiction treatments, likening it to the impact of Narcan.
14:45
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- GLP-1 medications not only assist in reducing food cravings but also show promise in addressing cravings for substances like alcohol and opioids.
- Increasing access to GLP-1s through policy reforms and innovation is essential to improve treatment options for the vast majority of individuals with substance use disorders.
Deep dives
Therapeutic Potential of GLP-1s
GLP-1 medications, primarily known for their effectiveness in treating diabetes and aiding weight loss, also show promising potential for addressing cravings associated with substance use disorders. Research indicates that these drugs not only help patients reduce cravings for food but may also impact cravings for alcohol and other substances like opioids and stimulants. Nicholas Revell from Casper notes that while there is considerable evidence supporting the safety and efficacy of GLP-1s, more focused research on their use for addiction is necessary. Ongoing clinical trials aim to explore their effects on overdose rates in veterans and those with alcohol use disorders, potentially revolutionizing treatment options in addiction medicine.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
